In 1988, George Daley and David Baltimore established that BCR-ABL—the gene fusion product found in almost every case of chronic myelogenous leukemia (CML) [1]—was oncogenic using the murine Ba/F3 cell line [2]. Here, BCR is linked to chronic myelogenous leukemia, BCR-ABL1 positive.